204 related articles for article (PubMed ID: 31018022)
21. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS
Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751
[TBL] [Abstract][Full Text] [Related]
22. Endosomal gene expression: a new indicator for prostate cancer patient prognosis?
Johnson IR; Parkinson-Lawrence EJ; Keegan H; Spillane CD; Barry-O'Crowley J; Watson WR; Selemidis S; Butler LM; O'Leary JJ; Brooks DA
Oncotarget; 2015 Nov; 6(35):37919-29. PubMed ID: 26473288
[TBL] [Abstract][Full Text] [Related]
23. MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.
Pallua JD; Schaefer G; Seifarth C; Becker M; Meding S; Rauser S; Walch A; Handler M; Netzer M; Popovscaia M; Osl M; Baumgartner C; Lindner H; Kremser L; Sarg B; Bartsch G; Huck CW; Bonn GK; Klocker H
J Proteomics; 2013 Oct; 91():500-14. PubMed ID: 23954705
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer.
Park YH; Shin HW; Jung AR; Kwon OS; Choi YJ; Park J; Lee JY
Sci Rep; 2016 Aug; 6():30386. PubMed ID: 27503267
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
27. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
28. Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis.
Pang B; Zhu Y; Ni J; Thompson J; Malouf D; Bucci J; Graham P; Li Y
Theranostics; 2020; 10(5):2309-2326. PubMed ID: 32089744
[TBL] [Abstract][Full Text] [Related]
29. Distinct prostate cancer-related mRNA cargo in extracellular vesicle subsets from prostate cell lines.
Lázaro-Ibáñez E; Lunavat TR; Jang SC; Escobedo-Lucea C; Oliver-De La Cruz J; Siljander P; Lötvall J; Yliperttula M
BMC Cancer; 2017 Feb; 17(1):92. PubMed ID: 28143451
[TBL] [Abstract][Full Text] [Related]
30. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
[TBL] [Abstract][Full Text] [Related]
31. A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.
Leyh-Bannurah SR; Trudel D; Latour M; Zaffuto E; Grosset AA; Tam C; Ouellet V; Graefen M; Budäus L; Aprikian AG; Lacombe L; Fleshner NE; Gleave ME; Mes-Masson AM; Saad F; Karakiewicz PI
Pathol Oncol Res; 2019 Jul; 25(3):979-986. PubMed ID: 29623528
[TBL] [Abstract][Full Text] [Related]
32. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
Noske A; Weichert W; Niesporek S; Röske A; Buckendahl AC; Koch I; Sehouli J; Dietel M; Denkert C
Cancer; 2008 Apr; 112(8):1733-43. PubMed ID: 18306389
[TBL] [Abstract][Full Text] [Related]
33. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer.
Meller S; Meyer HA; Bethan B; Dietrich D; Maldonado SG; Lein M; Montani M; Reszka R; Schatz P; Peter E; Stephan C; Jung K; Kamlage B; Kristiansen G
Oncotarget; 2016 Jan; 7(2):1421-38. PubMed ID: 26623558
[TBL] [Abstract][Full Text] [Related]
34. Evidence for Adipocyte-Derived Extracellular Vesicles in the Human Circulation.
Connolly KD; Wadey RM; Mathew D; Johnson E; Rees DA; James PE
Endocrinology; 2018 Sep; 159(9):3259-3267. PubMed ID: 30016424
[TBL] [Abstract][Full Text] [Related]
35. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
36. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
[TBL] [Abstract][Full Text] [Related]
37. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
38. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
[TBL] [Abstract][Full Text] [Related]
39. Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy.
Bi XC; Liu JM; Zheng XG; Xian ZY; Feng ZW; Lou YX; Zhong WD; Wu CL
Clin Invest Med; 2011 Dec; 34(6):E358. PubMed ID: 22129926
[TBL] [Abstract][Full Text] [Related]
40. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]